- Home
- NA vs UNCY Comparison
NA vs UNCY Comparison
Compare NA & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NA
- UNCY
- Stock Information
- Founded
- NA 2019
- UNCY 2016
- Country
- NA China
- UNCY United States
- Employees
- NA N/A
- UNCY N/A
- Industry
- NA Semiconductors
- UNCY Biotechnology: Pharmaceutical Preparations
- Sector
- NA Technology
- UNCY Health Care
- Exchange
- NA Nasdaq
- UNCY Nasdaq
- Market Cap
- NA 32.3M
- UNCY 31.9M
- IPO Year
- NA 2022
- UNCY 2021
- Fundamental
- Price
- NA $4.42
- UNCY $0.46
- Analyst Decision
- NA
- UNCY Strong Buy
- Analyst Count
- NA 0
- UNCY 4
- Target Price
- NA N/A
- UNCY $5.50
- AVG Volume (30 Days)
- NA 162.9K
- UNCY 1.9M
- Earning Date
- NA 09-18-2024
- UNCY 11-13-2024
- Dividend Yield
- NA N/A
- UNCY N/A
- EPS Growth
- NA N/A
- UNCY N/A
- EPS
- NA N/A
- UNCY N/A
- Revenue
- NA $6,991,446.00
- UNCY N/A
- Revenue This Year
- NA N/A
- UNCY N/A
- Revenue Next Year
- NA N/A
- UNCY N/A
- P/E Ratio
- NA N/A
- UNCY N/A
- Revenue Growth
- NA N/A
- UNCY N/A
- 52 Week Low
- NA $2.75
- UNCY $0.20
- 52 Week High
- NA $47.50
- UNCY $1.82
- Technical
- Relative Strength Index (RSI)
- NA 45.38
- UNCY 48.64
- Support Level
- NA $2.77
- UNCY $0.41
- Resistance Level
- NA $9.68
- UNCY $0.55
- Average True Range (ATR)
- NA 1.36
- UNCY 0.06
- MACD
- NA -0.02
- UNCY -0.01
- Stochastic Oscillator
- NA 23.88
- UNCY 23.47
About NA Nano Labs Ltd
Nano Labs Ltd operates as a fabless IC design company and product solution provider in China. It engages in the development of HTC chips, HPC chips, distributed computing and storage solutions, smart-NICs, vision computing chips, and distributed rendering. Its products comprise Cuckoo 1.0 Chip, Cuckoo 2.0 Chip, and Darkbird 1.0 Chip. Majority of the company revenue comes from China.
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's lead drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury.